Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US6350752B1 · kind B1 · utility
Inventors
Key dates
| Filing date | Jun 19, 1997 |
| Grant date | Feb 26, 2002 |
| Priority date | — |
| Expiry date | Jun 19, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are methods and associated compositions and medicaments directed generally to the control of cellular and neural activity and for selectively and controllably inducing the in vivo genetic expression of one or more naturally occurring genetically encoded molecules in mammals. More particularly, the present invention selectively activates or derepresses genes encoding for specific naturally occurring molecules such as proteins or neurotrophic factors and induces the endogenous production of such naturally occurring compounds through the administration of carbon monoxide dependent guanylyl cyclase modulating purine derivatives. The methods of the present invention may be used to affect a variety of cellular and neurological functions and activities and to therapeutically or prophylactically treat a wide variety of neurodegenerative, neurological, cellular, and physiological disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.